Summary
Intravenous, oral and intraportal doses of diperdipine were given to bile duct cannulated dogs in order to assess the impact of first pass effect on the pharmacokinetics of this compound.
After intravenous and oral doses, absolute bioavailability was calculated to be 18.7%. Biliary excretion accounted for about 0.1% of the total clearance of diperdipine and did not contribute to the overall elimination of the drug.
After intraportal administration, the bioavailable fraction of diperdipine was increasing up to 44.3% suggesting a prehepatic site of loss of the drug. This was also substantiated by the fact that after oral administration a lesser fraction was excreted in the bile, than after the intraportal dose. The drug was highly bound to plasma proteins (>96%) and was largely distributed in the blood cells for which a concentration dependent process was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Greiner P.O., Angignard D., Cahn J. (1988): High performance liquid chromatography of a new 1,4-dihydropyridine: applications to pharmacokinetic study in dogs. J. Pharm. Sci., 77, 387–389.
Krause H.P., Ahr H.J., Beermann D., Siefert H.M., Suwelack D., Weber H. (1988): The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations and excretion after single administration of14C nitrendipine to rats and dogs. Arzneimittelforsch., 38, 1593–1599.
Ahr H.J., Krause H.P., Siefert H.M., Suwelack D., Weber H. (1988): Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma and excretion after single administration of14C nisoldipine in rats, dogs, monkeys and swine. Arzneimittelforsch., 38, 1093–1098.
Garrett E.R., Jackson A.J. (1979): Pharmacokinetics of morphine and its surrogates. III: morphine and morphine 3-monoglucuronide. Pharmacokinetics in the dogs as a function of dose. J. Pharm. Sci., 68, 753–771.
Bäärnhielm C., Dahlbäck H., Skänberg I. (1986): In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol. Toxicol., 59, 113–122.
Niwa T., Tokuma Y., Nakagawa K., Noguchi H. (1989): Stereoselective oxidation of nilvadipine, a new dihydropyridine calcium antagonist, in rat and dog liver. Drug Metab. Dispos., 17, 64–68.
Mahrun D., Siefert H.M., Weber H., Rämsch K., Suwelack D. (1985): Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of14C nimodipine in rat, dog and monkey. Arzneimittelforsch., 35, 1781–1786.
Higuchi S., Shiobara Y. (1980): Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species, in vitro. Xenobiotica, 10, 889–896.
Higuchi S., Sasaki H., Shiobara Y., Sado T. (1977): Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs. Xenobiotica, 7, 469–479.
Abemethy D.R., Schwartz J.B. (1988): Pharmacokinetics of calcium antagonists under development. Clin. Pharmacokinet., 15, 1–14.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greiner, P.O., Weber, S., Angignard, J. et al. Evaluation of first pass effect and biliary excretion of diperdipine in the dog. Eur. J. Drug Metab. Pharmacokinet. 15, 185–190 (1990). https://doi.org/10.1007/BF03190202
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190202